Pidotimod is commonly used in patients, including both pediatric and adult groups, who experience recurrent respiratory tract infections (RRTIs), which are conditions marked by periods of heightened symptoms. The therapeutic scope is relevant for easing symptoms related to specific recurrent non-respiratory domains, including the management of recurrent urinary tract infections (UTIs) and specific periodic inflammatory syndromes, such as PFAPA syndrome. This use is associated with a reduced number of infectious episodes over time. It is generally applied when symptoms become more noticeable due to vulnerability to repeat infections.

The medication may also be part of symptomatic management during the acute phase of infection, especially for infectious exacerbations in individuals with chronic respiratory conditions, helping to manage symptoms that interfere with daily functioning, such as fever, cough, and runny nose (rhinorrhea). This may contribute to a more manageable duration of the infectious episode and eases the intensity of these acute manifestations. This focus on long-term stability provides a key benefit: “supports patients during difficult episodes by easing distress and assists with maintaining functional stability.”

---

Quick Fact: Relief for Recurrent Illness
Core Therapeutic Focus: Managing conditions characterized by frequent and repeated infectious episodes.
Key Symptom Support: Helping to address symptom clusters associated with recurrent fevers, pharyngitis, and painful urination in specific patient groups.
Context of Use: Applied across domains where the primary issue is the risk of symptomatic relapses.

Regulatory References

1. ClinicalTrials.gov entry on Pidotimod for RRI

Eligibility Scope

The eligibility for Pidotimod is strictly defined by regulatory documents, which establish specific criteria for patient populations.

Category	Official Regulatory Status
Populations for whom use is allowed	Adults, older adults, and pediatric patients from the age of 3 years and older.
Populations for whom use is not recommended	Pregnant women (especially the first trimester) and women who are breastfeeding.
Populations for whom use is contraindicated	Patients with a known hypersensitivity to Pidotimod or its components; individuals receiving immunosuppressive treatment.
Age-related eligibility rules	Not recommended for use in children under 3 years of age, as safety and efficacy are not established in this age group.
Condition-specific eligibility rules	Use requires caution in patients with severely impaired kidney function (renal impairment).

---

Eligibility Classifications (High-Level)

Category	Official Regulatory Classification
Eligibility severity classification	Contraindicated (Hypersensitivity, Immunosuppressants), Not Recommended (Pregnancy, Lactation, Children <3 years), Use with Caution (Renal Impairment).

---

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use Pidotimod by establishing absolute contraindications that prohibit use in certain groups. They also define conditional use for patients with severely impaired kidney function and explicitly restrict use during pregnancy and breastfeeding. The medicine’s use is officially established only for children aged 3 years and older.

Interactions with other medicines and products

Pharmacodynamic and Contraindicated Combinations

The interaction profile for Pidotimod includes specific restrictions related to its immunomodulatory function. Immunosuppressive treatment is a contraindicated combination in official prescribing information, as co-administration could potentially interfere with the medicine's intended effects on the immune system. A potential pharmacodynamic interaction is also noted with other medicines that block or stimulate lymphocyte activity, such as Thymostimulin.

---

Pharmacokinetic Interaction with Food

A significant pharmacokinetic interaction is documented regarding food intake. Official regulatory sources confirm that consuming Pidotimod with a meal can substantially reduce its oral bioavailability by up to 50%. To address this quantified reduction in systemic exposure, a mandatory timing separation is required: Pidotimod must be administered either two hours before or two hours after eating.

---

Metabolic Interaction Potential

Piditomod is known to undergo minimal metabolism in the liver and exhibits low plasma protein binding. Based on this, no significant pharmacokinetic interactions are generally expected with other medicinal products that are typically eliminated via major liver enzyme pathways. No specific interactions are documented in regulatory summaries concerning alcohol, herbal products, or supplements.

Modulation of Non-Specific Immune Signaling

Pidotimod engages mechanisms that regulate overactive or dysregulated processes within the innate immune system. It modifies early molecular steps in the signaling sequences, primarily impacting the activity of cells like macrophages and natural killer (NK) cells. This action influences feedback regulation within targeted signaling pathways of the non-specific immune response.

---

Regulation of Lymphocyte Activity and Maturation

The drug acts within domains involving receptor- or enzyme-mediated signaling to influence adaptive immunity. Specifically, Pidotimod initiates or suppresses signaling sequences that lead to downstream effects on T-lymphocyte maturation and function, as well as B-lymphocyte antibody production. This modifies signaling sequences that influence the magnitude of physiological responses and modulates innate and adaptive pathway cross-talk.

---

Influence on Cytokine and Mediator Release

Pidotimod is relevant in systems where targeted pathway adjustment is required concerning pro- and anti-inflammatory mediators. It modulates the transcription and release kinetics of immune mediators by altering the transcriptional and release patterns of key cytokines (e.g., IL-2, TNF-alpha). This produces changes in downstream biochemical parameters that support balanced immune communication.

Administration Route and Forms

Pidotimod is strictly for oral administration, utilizing approved dosage forms such as tablets (e.g., 400 mg and 800 mg strengths) or oral solutions (syrup, batches). The administration protocol is typically structured into two distinct phases: an initial phase and a prolonged maintenance or prophylactic phase, each with a defined regimen.

---

Official Dosing and Schedule Patterns

Official regulatory guidelines define specific dose units and frequencies. For adults, the standard dose during an acute phase is 800 mg taken twice daily, while the maintenance dose is 800 mg taken once daily. For children above the minimum eligible age of three years, the regimen is 400 mg taken twice daily for the acute phase, reducing to 400 mg once daily for maintenance.

Patient Population	Acute Phase Dosing	Maintenance/Prophylaxis Dosing
Adults	800 mg twice daily	800 mg once daily
Children (>3 years)	400 mg twice daily	400 mg once daily

---

Administration Conditions and Duration

To ensure optimal absorption, the medicine must be taken on an empty stomach. Official instructions specify that Pidotimod should be administered two hours before or two hours after food. The duration of use is also regulated: the acute treatment course is typically 15 to 20 days, followed by a longer prophylactic course that can last approximately 60 days. If a dose is missed, regulatory documents advise taking it as soon as remembered, unless it is almost time for the next dose; in such a case, the missed dose is skipped, and the scheduled regimen is resumed without doubling the subsequent dose. Dose adjustments may be necessary for patients with renal failure.

Research Evidence / Overview of Studies for Pidotimod

---

Evidence for Use in Recurrent Respiratory Tract Infections (RRTIs)

Research has widely examined Pidotimod in the context of individuals who experience frequent and repeated infections of the upper and lower respiratory tract, a condition characterized by fluctuating or episodic manifestations. This area has been studied for the largest body of evidence, including numerous Randomized Controlled Trials (RCTs) and summaries compiled in Meta-analyses. These studies primarily examined children who had experienced a history of recurrent infections, though adults were also included in some research.

Researchers specifically monitored the frequency of recurrent infectious episodes and observing how symptoms like fever and cough evolved during the study period. Findings described patterns observed in the studies, which included the measured frequency of infectious episodes in the studied group compared to the control group. Research also highlights measurements recorded related to the duration and severity of acute symptoms and data show patterns related to the documented use of symptomatic medication and antibiotics.

Evidence for Use in Other Recurrent or Chronic Situations

Pidotimod was also studied in the context of other situations, specifically conditions involving periods of heightened symptoms that are not respiratory-related, such as recurrent urinary tract infections (UTIs) and chronic conditions like Chronic Obstructive Pulmonary Disease (COPD). The outcomes studies explored were often related to functional imbalance and outcomes describing episodic or acute changes. Findings were mixed and the evidence remains limited across this diverse range of conditions. Some observational studies described patterns related to the frequency of recurrence in certain patient groups, but comparative evidence is lacking.

---

What Is Still Uncertain About the Research

Research highlights what is known — and what is still uncertain — about Pidotimod. Scientific reviews note that the overall modest sample sizes and methodological variability mean that evidence quality varies across studies, particularly for less-common indications. There is a clear need for further high-quality research to confirm many of the reported patterns. Additionally, long-term effects are not fully established, as follow-up durations were limited, leaving uncertainty regarding sustained outcomes beyond one year.

Key Studies & References

1. ClinicalTrials.gov Entry: Pidotimod in Prevention of Recurrent Respiratory Infections in Children

Common questions about Pidotimod (FAQ)

Q: Are there different brand names for the drug Pidotimod?

Yes, Pidotimod is the active ingredient, or International Nonproprietary Name (INN). According to various regulatory and commercial drug databases, the medicine is marketed under several different brand names across the world, such as Adimod, Axil, Imunorix, and Polimod.

---

Q: How does Pidotimod differ from popular vitamins or supplements for immunity?

Pidotimod is a chemically defined, synthetic dipeptide molecule. It is formally classified by regulatory bodies as an immunomodulator (ATC code L03AX05) due to its specific action on immune cells. Its classification as an immunomodulator and synthetic molecule differentiates it from vitamins or general dietary supplements.

---

Q: Is Pidotimod widely approved in countries outside of Italy?

Pidotimod has been used in Italy since 1993, which is one of the main countries of origin for its clinical use. Official data and global clinical studies confirm that the medicine is also approved and currently used in numerous other countries, particularly across Asia and Latin America.

---

Q: Does Pidotimod require a prescription from a doctor?

Yes, Pidotimod is regulated as a prescription drug. Official sources state that the medicine is intended for use only as directed by a healthcare professional, according to official prescribing guidelines.

---

Q: Is Pidotimod known to cause drowsiness or affect driving?

Official regulatory information advises that the use of this medicine may cause drowsiness in some patients. If symptoms such as drowsiness or dizziness occur, official information advises patients to exercise caution when driving or operating machinery.

---

Q: Is there any risk of becoming dependent on Pidotimod?

Regulatory safety assessments indicate that Pidotimod does not exhibit habit-forming tendencies. No cases of dependence or addiction have been reported in official product information.

---

Q: Is hair loss listed as a possible side effect of Pidotimod?

Based on the safety data collected during clinical trials and post-marketing surveillance, hair loss (alopecia) is not listed among the common or uncommon side effects documented in the official prescribing information.

---

Q: Does taking Pidotimod affect the effectiveness of vaccines?

The medicine’s immunomodulatory properties have been examined in relation to vaccinations. Research has suggested that Pidotimod may be associated with changes in specific parameters of the immune response after vaccination, which is a subject of ongoing study.

---

Q: Is Pidotimod ever used in combination with conventional antibiotics?

Yes, official use guidelines support the use of Pidotimod in combination with standard medical therapy. This includes its use in combined therapy with conventional antibiotics for the treatment of certain infections. It is sometimes described as an adjuvant (an assisting agent) when used in combination with antibiotics.

---

Q: Are there any regulatory warnings or black box statements associated with Pidotimod?

Official regulatory documents typically do not contain a black box warning for Pidotimod. The main safety restriction noted is the absolute contraindication (prohibition of use) for patients with a known allergy or hypersensitivity to the drug's components.

---

Q: How quickly does Pidotimod work in the body after it is taken?

Pharmacokinetic studies show that Pidotimod is quickly absorbed after it is taken orally. The maximum concentration of the medicine in the blood is typically reached within the first one to two hours after it is taken.

---

Q: What happens if a person accidentally takes too much Pidotimod?

As with any medicine, it is important to strictly follow the dose as prescribed. Regulatory documents state that if an overdose is suspected, one should immediately seek emergency medical attention or contact a doctor or Poison Control Center.

---

Q: Can Pidotimod be used by individuals who have diabetes?

Regulatory information indicates that the use of Pidotimod requires caution for patients who have diabetes. Official documentation notes that monitoring of blood glucose levels may be considered during treatment.

---

Q: How long has Pidotimod been available for public use?

Pidotimod is not a new medicine. It was first developed in the 1980s and was officially introduced for clinical use in countries such as Italy in 1993. Since then, it has been available and used in various countries worldwide.

---

Q: Does Pidotimod affect blood test results or lab work?

Since Pidotimod is an immunomodulator, its intended action is to regulate the immune system. The action of Pidotimod has been observed to influence certain laboratory parameters associated with immune function, such as the activity of specific immune cells.

---

Q: Is Pidotimod similar to other drugs that boost white blood cells?

Pidotimod is classified as an immunomodulator. Its function is described as stimulating and enhancing the activity of various immune cells, including those known generally as white blood cells (such as macrophages and neutrophils). This action helps regulate the body’s defenses.

---

Q: Is Pidotimod often used alongside chemotherapy or other cancer treatments?

Official product information states that Pidotimod is contraindicated (should not be used) in patients receiving immunosuppressive treatment. This restriction is due to the potential for interference with the drug's intended action on the immune system.

---

Q: Do any official sources mention the potential for Pidotimod to interact with birth control?

Pidotimod is known to undergo minimal breakdown by the liver. Official sources note that no significant pharmacokinetic interactions are generally expected with other medicines that are eliminated via major liver enzyme pathways, which includes most oral contraceptives.

---

Q: Is Pidotimod considered a drug that needs special monitoring?

While Pidotimod is generally well-tolerated, special monitoring is advised for certain patient populations. Regulatory information indicates that caution and special monitoring (such as of kidney function or blood glucose levels) are advised for individuals with severely reduced kidney function or those with diabetes.

The storage and disposal of Pidotimod must strictly adhere to the conditions mandated by regulatory labeling to maintain the medicine’s stability and ensure safe handling.

Storage Requirement	Official Regulatory Statement
Temperature	Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Protection	Keep the container tightly closed and store in the original package to protect the medicine from moisture and light.
Child Safety	The product must be stored out of the sight and reach of children.
Disposal	Unused or expired Pidotimod must not be thrown into household trash or flushed down the toilet. Disposal must follow official local regulations for pharmaceutical waste, such as a drug take-back program.